Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren’s syndrome in mice

[1]  S. Reppe,et al.  Elevated cytokine levels in tears and saliva of patients with primary Sjögren’s syndrome correlate with clinical ocular and oral manifestations , 2019, Scientific Reports.

[2]  C. Webber,et al.  Antiviral activity of bone morphogenetic proteins and activins , 2018, Nature Microbiology.

[3]  Junji Xu,et al.  Effect of Bone Morphogenetic Protein 6 on Immunomodulatory Functions of Salivary Gland-Derived Mesenchymal Stem Cells in Sjögren's Syndrome. , 2018, Stem cells and development.

[4]  Yingying Su,et al.  Bone Morphogenetic Protein 6 Inhibits the Immunomodulatory Property of BMMSCs via Id1 in Sjögren's Syndrome , 2018, Stem cells international.

[5]  J. Chiorini,et al.  Cross-contamination of the human salivary gland HSG cell line with HeLa cells: A STR analysis study. , 2018, Oral diseases.

[6]  L. Criswell,et al.  2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts , 2017, Arthritis & rheumatology.

[7]  J. Chiorini,et al.  Aquaporin gene therapy corrects Sjögren’s syndrome phenotype in mice , 2016, Proceedings of the National Academy of Sciences.

[8]  N. Billestrup,et al.  Inflammatory Cytokines Stimulate Bone Morphogenetic Protein-2 Expression and Release from Pancreatic Beta Cells. , 2016, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[9]  R. Priori,et al.  Sex differences in Sjögren’s syndrome: a comprehensive review of immune mechanisms , 2015, Biology of Sex Differences.

[10]  Zuping He,et al.  The Function and Regulation of BMP6 in Various Kinds of Stem Cells. , 2015, Current pharmaceutical design.

[11]  S. Cha,et al.  Mouse Models of Primary Sjogren's Syndrome. , 2015, Current pharmaceutical design.

[12]  J. Chiorini,et al.  Matriptase Deletion Initiates a Sjögren’s Syndrome-Like Disease in Mice , 2014, PloS one.

[13]  G. Illei,et al.  Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in mice. , 2013, Arthritis and rheumatism.

[14]  Lingying Ye,et al.  Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[15]  A. Bullock,et al.  Development of an ALK2-biased BMP type I receptor kinase inhibitor. , 2013, ACS chemical biology.

[16]  P. ten Dijke,et al.  BMP signaling in vascular diseases , 2012, FEBS letters.

[17]  J. Nickel,et al.  Promiscuity and specificity in BMP receptor activation , 2012, FEBS letters.

[18]  J. Chiorini,et al.  Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome , 2012, Arthritis Research & Therapy.

[19]  L. Criswell,et al.  Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. , 2011, Arthritis and rheumatism.

[20]  A. Tzioufas,et al.  Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome , 2010, Nature Reviews Rheumatology.

[21]  C. Hong,et al.  Applications of small molecule BMP inhibitors in physiology and disease. , 2009, Cytokine & growth factor reviews.

[22]  Tomokazu Fukuda,et al.  BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.

[23]  X. Mariette,et al.  Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. , 2007, Arthritis and rheumatism.

[24]  B. O'Connell,et al.  Morphological and functional differentiation of HSG cells: Role of extracellular matrix and trpc 1 , 2007, Journal of cellular physiology.

[25]  S. Nielsen,et al.  Successful treatment of a patient with primary Sjögren's syndrome with Rituximab , 2006, Clinical Rheumatology.

[26]  S. Cha,et al.  Sjögren's Syndrome‐Like Disease of C57BL/6.NOD‐Aec1 Aec2 Mice: Gender Differences in Keratoconjunctivitis Sicca Defined by a Cross‐Over in the Chromosome 3 Aec1 Locus , 2006, Scandinavian journal of immunology.

[27]  Brij B. Singh,et al.  A Role for AQP5 in Activation of TRPV4 by Hypotonicity , 2006, Journal of Biological Chemistry.

[28]  C. Eng,et al.  From developmental disorder to heritable cancer: it's all in the BMP/TGF-β family , 2003, Nature Reviews Genetics.

[29]  M. Humphreys-Beher,et al.  Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. , 2002, Arthritis and rheumatism.

[30]  Carissa M Krane,et al.  Salivary Acinar Cells from Aquaporin 5-deficient Mice Have Decreased Membrane Water Permeability and Altered Cell Volume Regulation* , 2001, The Journal of Biological Chemistry.

[31]  R. Kiss,et al.  Abnormal Distribution of Aquaporin-5 Water Channel Protein in Salivary Glands from Sjögren’s Syndrome Patients , 2001, Laboratory Investigation.

[32]  J. Massagué,et al.  Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway , 1999, Nature.

[33]  J. Massagué,et al.  Determinants of specificity in TGF-beta signal transduction. , 1998, Genes & development.

[34]  R. Fox,et al.  Sjögren's syndrome , 1995, The Lancet.

[35]  R. Fox,et al.  Sjögren's syndrome. , 1994, Clinics in dermatology.

[36]  Charles C Hong,et al.  Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. , 2008, Nature chemical biology.

[37]  C. Eng,et al.  From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. , 2003, Nature reviews. Genetics.

[38]  J. Massagué,et al.  Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. , 1999, Nature.